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incture of Time
hen to Implant a Prophylactic
ardioverter-Defibrillator
ollowing Coronary Revascularization?*
nne M. Gillis, MD, FRCP(C)
algary, Alberta, Canada
he implantable cardioverter-defibrillator (ICD) has been
hown to prevent cardiovascular mortality and sudden
ardiac death in high-risk patients, particularly those with
ignificantly depressed left ventricular function after a re-
ote myocardial infarction (1,2). However, not all patients
n this high-risk group experience a benefit from the ICD
3,4). The Coronary Artery Bypass Graft (CABG)-Patch
rial Investigators previously reported that a prophylactic
CD did not confer a survival benefit for patients with left
entricular dysfunction undergoing coronary artery bypass
urgery, thus supporting the importance of coronary artery
evascularization for the prevention of sudden death in this
igh-risk group (4).
See page 1811
In this issue of the Journal, Goldenberg et al. (5) report
he effects of elapsed time following coronary revasculariza-
ion on the benefits of a prophylactic ICD in a subset of the
ulticenter Automatic Defibrillator Implantation Trial
MADIT)-II. These investigators observed that patients
nrolled more than six months following coronary revascu-
arization enjoyed a significant survival benefit due to the
CD, whereas no survival benefit was found in the group
nrolled six months or less following revascularization. The
uthors conclude that this effect was due to the low risk of
udden cardiac death early after coronary revascularization.
he authors suggest that implantation of a prophylactic
CD can be deferred for a period of time following coronary
evascularization.
The observations of this study are mechanistically intui-
ive. Acute ischemia is believed to be an important trigger
or sudden death due to sustained ventricular arrhythmias. If
ulprit vessels are successfully revascularized and recurrent
schemia prevented, the risk of sudden death should be
meliorated (6). Nevertheless, the risk of sudden death in
he MADIT-II population did increase more than six
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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eceived lecture fees from Medtronic and Guidant.onths after coronary revascularization. Whether this in-
reased risk of sudden death over time reflects the incom-
leteness of coronary artery revascularization or progression
f coronary artery disease in other vessels is uncertain. No
ata are available concerning the completeness of revascu-
arization in the MADIT-II study population. It is possible
hat differences in risk for sudden death after revasculariza-
ion are influenced by the number of diseased vessels and the
ompleteness of the revascularization procedure (7). Com-
ared to percutaneous coronary intervention, coronary ar-
ery bypass surgery provides more complete revascularization
f the coronary arteries. Patients with revascularization within
ix months of receiving an ICD were more likely to have
ndergone percutaneous coronary intervention, whereas pa-
ients undergoing ICD implantation more than six months
fter revascularization were much more likely to have
ndergone coronary artery bypass surgery. Although the
ample size in this study was too small to permit a detailed
omparison of the type of revascularization procedure on the
isk of sudden death early and late following coronary
evascularization, the data do suggest that both approaches
re associated with similar low rates of sudden death early
fter revascularization.
It is possible that patients who were enrolled in the
ADIT-II study early after revascularization were sicker,
ith more heart failure and thus at increased risk of
on-sudden cardiac death. Against this hypothesis, patients
eceiving an ICD early after revascularization had better-
reserved left ventricular systolic function (5).
Do the present study observations apply to the MADIT-
I–like population in 2006? It is possible that advances in
herapy for coronary heart disease that have been introduced
ince the MADIT-II study commenced in 1997 might
onfer more protection from sudden cardiac death after
oronary revascularization than was reported in this study.
nly 65% of the MADIT-II population were on lipid-
owering therapy, and most were likely not on the higher
oses of statins that have been shown recently to prevent
ecurrent ischemia (8). Seventy percent of the MADIT-II
opulation were taking beta-blockers, and less than one-half
f those patients were taking carvedilol compared with other
eta-blockers (9). Carvedilol has been reported to signifi-
antly reduce cardiovascular mortality and sudden death
ompared with metoprolol (10). Whether higher utilization
f beta-blockers, and carvedilol in particular, in this study
opulation would extend the benefits of coronary revascu-
arization for prevention of sudden death is unknown.
hether the increased use of drug-eluting stents and greater
uccess with multivessel revascularization using percutaneous
oronary interventions would influence the risk of sudden
eath in this population also is unknown.
These study results suggest that there is no need to rush
o implant a prophylactic ICD after coronary revasculariza-
ion. The data indicate that implantation of a prophylactic
CD could be deferred for up to six months after coronary
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May 2, 2006:1818–9 Editorial Commentevascularization. This approach would allow reassessment
f ventricular function after revascularization to identify
hose patients who might experience a significant improve-
ent in systolic function as a consequence of recovery of
tunned or hibernating myocardium (11,12). Such patients
ight no longer fit the criteria for a prophylactic ICD. To
ate, the impact of coronary revascularization on recovery of
ystolic function and subsequent risk for sudden cardiac
eath has not been studied in the MADIT-II–like patient
opulation.
The results of the CABG-Patch study (3) and this more
ecent MADIT-II subgroup analysis (5) confirm the im-
ortance of coronary revascularization for the prevention of
udden cardiac death. Whether recent advances in the
reatment of coronary heart disease have altered the risk of
udden death over a longer time frame following revascu-
arization procedures or whether completeness of the revas-
ularization procedure modifies the risk of sudden death will
equire further study.
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